Structural and Functional Magnetic Resonance Imaging : Mild Cognitive Impairment and Alzheimer Disease - 02/10/13

Doi : 10.1016/j.cpet.2013.08.004

Hannah Lockau, MD ^a, Frank Jessen, MD ^b, Andreas Fellgiebel, MD ^c, Alexander Drzezga, MD ^d,^⁎
^a Department of Radiology, University Hospital Cologne, Kerpener Street 62, Cologne 50937, Germany
^b Department of Psychiatry, German Center for Neurodegenerative Diseases (DZNE), University of Bonn, Sigmund-Freud-Straße 25, Bonn 53105, Germany
^c Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Untere Zahlbacher Street 8, Mainz 55131, Germany
^d Department of Nuclear Medicine, University Hospital Cologne, Kerpener Street 62, Cologne 50937, Germany

^∗Corresponding author.

Résumé

Magnetic resonance (MR) imaging is playing an increasingly pivotal role in the clinical management of dementia, including Alzheimer disease (AD). In addition to established MR imaging procedures, the introduction of advanced instrumentation such as 7-T MR imaging, as well as novel MR imaging sequences such as arterial spin labeling, MR spectroscopy, diffusion tensor imaging, and resting-state functional MR imaging, may open new pathways toward improved diagnosis of AD even in early stages of disease such as mild cognitive impairment (MCI). This article describes the typical findings of established and new MR imaging procedures in healthy aging, MCI, and AD.

Le texte complet de cet article est disponible en PDF.

Keywords : Alzheimer disease, Dementia, Mild cognitive impairment, Magnetic resonance imaging, Diffusion tensor imaging, Arterial spin labeling, Magnetic resonance spectroscopy

Plan

Key points

Introduction

MR imaging–based exclusion of non-neurodegenerative causes of cognitive impairment

MR imaging methods for specific assessment of neurodegenerative changes

Structural imaging

Diffusion tensor imaging

Arterial spin labeling

Proton MR spectroscopy

Functional MR imaging activation studies

Resting-state functional connectivity

Multimodal approaches

Summary

Disclosures: This work was supported by grants of the German Research Foundation (DFG) DR 445/4-1 to Alexander Drzezga. Alexander Drzezga has worked as a consultant for Bayer Healthcare, Siemens Healthcare, GE Healthcare, Piramal, Avid/Lilly Pharmaceuticals. Andreas Fellgiebel acts as a consultant for GE Healthcare and Avid/Lilly Pharmaceuticals. Frank Jessen received consultation fees and speakers honoraria from GE Healthcare, Lilly, Novartis, Esai, Pfizer, Jansen-Cilag, Schwabe and Nutricia.